Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

GNC Reaches Deal With NY AG Over Herbal Plus Products

By Pharmaceutical Processing | March 30, 2015

NEW YORK (AP) — GNC Holdings Inc. said Monday that it has reached a deal with New York Attorney General Eric Schneiderman over its Herbal Plus products.

In February, Schneiderman’s office sent letters to GNC, Target, Walmart and Walgreens for allegedly selling store brand herbal supplement products in New York that either could not be verified to contain the labeled substance or were found to contain ingredients not listed on the labels.

The company said its agreement affirms the relevant products were in full compliance with federal Food and Drug Administration “Current Good Manufacturing Practices.” The agreement also recognizes GNC’s full cooperation with the attorney general’s inquiries.

GNC said that in responding to the attorney general, it provided results of internal tests and those conducted by independent third parties. The Pittsburgh company said the tests gave “conclusive evidence” that its products are safe, properly labeled and in full compliance with regulatory requirements.

In addition, GNC said that the tests showed that its products contain all herbal extracts listed on their respective labels.

The retailer said the full assortment of Herbal Plus products have returned to all of its stores in the state of New York. The company also said it will expand its testing processes for supplement suppliers.

GNC said that lawsuits were filed against it after the New York Attorney General’s announcement in February. The company said that it believes the lawsuits are “completely without merit” and that it will defend itself aggressively.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE